IPP Bureau
Amgen completes acquisition of Horizon Therapeutics
By IPP Bureau - October 07, 2023
Advances Amgen's mission to serve patients with rare disease medicines
Ministry of Ayush to launch special campaign 3.0,
By IPP Bureau - October 06, 2023
The Main campaign started from October 2
Ministry of Ayush inaugurates the conference on Homeopathy in Kolkata
By IPP Bureau - October 06, 2023
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
Apollo launches Hyderabad's first homecare recovery program
By IPP Bureau - October 06, 2023
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates
By IPP Bureau - October 06, 2023
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba Capsule
By IPP Bureau - October 05, 2023
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules
By IPP Bureau - October 05, 2023
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets
By IPP Bureau - October 05, 2023
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
Emmes appoints Matt Bond as CFO
By IPP Bureau - October 05, 2023
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Alembic received 6 USFDA approvals during Q2FY24
By IPP Bureau - October 05, 2023
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Strides receives USFDA approval for Icosapent Ethyl capsules
By IPP Bureau - October 04, 2023
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Lupin launches patient support program ‘Humrahi‘ for diabetes management
By IPP Bureau - October 04, 2023
India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045
Aurobindo Pharma completes sale of Antibiotic business to Apitoria Pharma
By IPP Bureau - October 03, 2023
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
AstraZeneca Pharma India gets permission to import Palivizumab solution for injection
By IPP Bureau - October 03, 2023
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Zydus announces IND clearance of a novel Anti-PCSK9 candidate
By IPP Bureau - October 03, 2023
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
